Fig. 6
From: Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines
Oncolytic effect of intravenous CV-B3/2035A administration on EC xenografts in vivo. a A single dose (1 × 106 TCID50) of CV-B3/2035A or PBS (Mock) was administered intravenously (i.v.) into the nude mice bearing bilateral HEC-1-B xenografts (n = 5 per group). Tumor growth (solid symbols) and body weight (open symbols) of nude mice were monitored over a 20-day period. Statistical analysis was performed by two-way ANOVA. Data are shown in means ± SD. The symbols, †and #, represent the statistical significance of right and left lateral tumors between untreated and CV-B3/2035A-treated groups, respectively. Black arrows indicate treatments; ns, not significant. b Biodistribution of intravenously delivered CV-B3/2035A in tumor-bearing nude mice was analyzed at 2 and 6 days post-treatment by qRT-PCR. Data are shown in means ± SD (n = 3 per group)